Tourmaline Bio Net Current Debt 2020-2025 | TRML

Tourmaline Bio net current debt from 2020 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.

Tourmaline Bio Net Current Debt 2020-2025 | TRML

Tourmaline Bio net current debt from 2020 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$67.7B
Zoetis (ZTS)$65.3B
Daiichi Sankyo, - (DSNKY)$46.2B
Takeda Pharmaceutical (TAK)$45.9B
BeOne Medicines - (ONC)$31.6B
Sandoz Group AG (SDZNY)$25.8B
Summit Therapeutics (SMMT)$21.3B
Merck (MKKGY)$16.4B
Shionogi (SGIOY)$15.2B
United Therapeutics (UTHR)$13.6B
Neurocrine Biosciences (NBIX)$12.4B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.4B
Madrigal Pharmaceuticals (MDGL)$7.7B
Corcept Therapeutics (CORT)$7.6B
Grifols, S.A (GRFS)$7.3B
Stevanato Group S.p.A (STVN)$7.2B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Crinetics Pharmaceuticals (CRNX)$2.5B
Catalyst Pharmaceuticals (CPRX)$2.4B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B